成人可乐定过量:持续性心动过缓与中枢神经系统抑制,但无严重毒性
该研究为前瞻性中毒队列的回顾性分析,纳入1988-2015年133例可乐定中毒住院患者,其中108例急性过量(>200 μg)纳入分析。中位摄入剂量2100 μg,中位住院时间21小时,无死亡。68%出现GCS<15,29%出现瞳孔缩小,76%出现心动过缓(中位起病2.5小时,中位持续20小时),24%出现低血压,无心律失常。纳洛酮用于23例,仅1例记录到GCS部分改善,作者认为纳洛酮与结局改善无关。
要点
- 108例急性可乐定过量(>200 μg)患者中无死亡、无心律失常,中位住院时间21小时。
- 76%(82/108)出现心动过缓,中位起病时间为摄入后2.5小时,中位持续20小时。
- 68%(73/108)出现GCS<15,合并其他药物者昏迷(GCS<9)比例为12%(8/68),单用可乐定者为5%(2/40)。
- 24%(26/108)出现低血压,中位最低收缩压96 mmHg;3例摄入8000-12000 μg者出现早期高血压。
- 纳洛酮用于23例(中位总剂量2 mg),仅1例记录到GCS部分改善,作者认为纳洛酮与结局改善无关。
适用人群与场景
- 成人(中位年龄27岁,范围14-65岁)因可乐定过量(>200 μg)就诊于中毒住院患者。
- 纳入急性单次过量者;排除病历不可用者(14例)和分次摄入者(11例)。
诊断标准与关键阈值
- 可乐定过量定义为摄入剂量>200 μg。
- 昏迷定义为GCS<9。
处置流程与药物剂量
- 治疗包括活性炭(24例)、阿托品(8例)和纳洛酮(23例)。
- 纳洛酮中位总剂量为2 mg(IQR:1.2-2.4 mg),具体给药途径、频次原文未报告。
- 12/108例接受气管插管,其中仅2例为单用可乐定者。
- 中位住院时间21小时(IQR:14-35小时)。
红旗征与不能漏的情况
- 摄入剂量8000-12000 μg的3例患者出现早期高血压。
- GCS<9的昏迷患者需考虑气道保护,原文中12例接受气管插管。
- 心动过缓起病中位时间2.5小时、持续中位20小时,需持续监测。
研究设计与关键结果
- 研究类型为前瞻性中毒队列的回顾性分析,纳入1988-2015年133例可乐定中毒住院患者,其中108例急性过量(>200 μg)纳入分析;中位年龄27岁(14-65岁),女性68例。
- 单用可乐定者40例,合并其他药物者68例;中位摄入剂量2100 μg(IQR:400-15000 μg);中位住院时间21小时(IQR:14-35小时);无死亡。
- GCS<15者73/108(68%);昏迷(GCS<9)在合并其他药物组为8/68(12%),单用可乐定组为2/40(5%)。
- 瞳孔缩小31/108(29%);心动过缓82/108(76%),中位起病时间2.5小时(IQR:1.7-5.5小时),中位持续时间20小时(2.5-83小时),单用与合并用药组相似;无心律失常。
- 中位最低心率48次/分(IQR:40-57次/分),单用与合并用药组相似;单用可乐定过量组中剂量与最低心率显著相关(p=0.02)。
- 中位最低收缩压96 mmHg(IQR:90-105 mmHg);低血压26/108(24%);3例摄入8000-12000 μg者出现早期高血压。
- 纳洛酮用于23例,中位总剂量2 mg(IQR:1.2-2.4 mg),仅1例记录到GCS部分改善。
证据类型、等级与局限
- 证据类型:前瞻性队列的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 成人可乐定过量(>200 μg)以持续性心动过缓和轻中度中枢抑制为主,无死亡及心律失常,支持以监护和对症治疗为主的处置。
- 纳洛酮用于23例仅1例记录到GCS部分改善,作者认为纳洛酮与结局改善无关。
- 心动过缓中位持续20小时,需延长监测时间。
- 合并其他药物者昏迷比例更高(12% vs 5%),应特别关注合并摄入。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: There are limited reports of adult clonidine overdose. We aimed to describe the clinical effects and treatment of clonidine overdose in adults.
METHODS: This was a retrospective review of a prospective cohort of poisoned patients who took clonidine overdoses (>200 μg). Demographic information, clinical effects, treatment, complications (central nervous system and cardiovascular effects) and length of stay (LOS) were extracted from a clinical database or medical records.
RESULTS: From 133 admissions for clonidine poisoning (1988-2015), no medical record was available in 14 and 11 took staggered ingestions. Of 108 acute clonidine overdoses (median age 27 years; 14-65 years; 68 females), 40 were clonidine alone ingestions and 68 were clonidine with co-ingestants. Median dose taken was 2100 μg (interquartile range [IQR]: 400-15,000 μg). Median LOS was 21h (IQR: 14-35 h) and there were no deaths. Glasgow coma score [GCS] <15 occurred in 73/108 (68%), and more patients taking co-ingestants (8/68; 12%) had coma (GCS <9) compared to clonidine alone (2/40; 5%). Miosis occurred in 31/108 (29%) cases. Median minimum HR was 48 bpm (IQR: 40-57 bpm), similar between clonidine alone and co-ingestant overdoses. There was a significant association between dose and minimum HR for clonidine alone overdoses (p = 0.02). 82/108 (76%) had bradycardia, median onset 2.5 h post-ingestion (IQR: 1.7-5.5 h) and median duration 20 h (2.5-83 h), similar for clonidine alone and co-ingestant overdoses. There were no arrhythmias. Three patients ingesting 8000-12,000 μg developed early hypertension. Median minimum systolic BP was 96 mmHg (IQR: 90-105 mmHg) and hypotension occurred in 26/108 (24%). 12/108 patients were intubated, but only 2 were clonidine alone cases. Treatments included activated charcoal (24), atropine (8) and naloxone (23). The median total naloxone dose was 2 mg (IQR: 1.2-2.4 mg), but only one patient given naloxone was documented to respond with partial improvement in GCS.
DISCUSSION: Clonidine causes persistent but not life-threatening clinical effects. Most patients develop mild central nervous system depression and bradycardia. Naloxone was not associated with improved outcomes.
参考来源
- Isbister GK, Heppell SP, Page CB, et al. Adult clonidine overdose: prolonged bradycardia and central nervous system depression, but not severe toxicity. Clin Toxicol (Phila). 2017. PMID: 28107093. doi:10.1080/15563650.2016.1277234
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。